Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Review · April 27, 2022

Evidence-Based Management of MS Spasticity With Nabiximols Oromucosal Spray in Clinical Practice

Neurodegenerative Disease Management


Additional Info

Disclosure statements are available on the authors' profiles:

Neurodegenerative Disease Management
Evidence-based management of multiple sclerosis spasticity with nabiximols oromucosal spray in clinical practice: a 10-year recap
Neurodegener Dis Manag 2022 Apr 04;[EPub Ahead of Print], A Chan, CV Silván

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading